Biomedicine / 报道
Roche licenses ALK7 candidate; $1.16 billion is conditional
Rona Therapeutics announced October 13 an exclusive worldwide license to Roche for an investigational ALK7-targeting RNA-interference therapy. Its extrahepatic delivery approach targets fat-cell biology, distinct from appetite-focused incretin therapies.
Upfront and near-term milestones total up to 100 million dollars. A further 1.06 billion is conditional on development, regulatory and commercial milestones, with tiered royalties on global net sales. The headline 1.16 billion is not cash already paid.
Reducing visceral fat while preserving lean mass is the company’s development rationale, not demonstrated patient benefit in this announcement. No human efficacy data were supplied. The October 14 post follows an October 13 agreement.
Sources and further reading
edited
Selected through a verified followed account: @ChineseWSJ.